Epilepsy clinical trials at UCSF
8 in progress, 4 open to eligible people
Clinical Utility of Pediatric Whole Exome Sequencing
open to eligible people ages up to 18 years
The investigator aims to examine the clinical utility of WES, including assessment of a variety of clinical outcomes in undiagnosed pediatric cases.
Oakland, California and other locations
Evaluating the Role of Inflammation in Neonatal Epileptogenesis
open to all eligible people
The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.
Oakland, California and other locations
Neonatal Seizure Registry - Developmental Functional EValuation
open to eligible people ages 2-8
The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants that aims to evaluate childhood outcomes after acute symptomatic neonatal seizures, as well as examine risk factors for developmental disabilities and whether these are modified by parent well-being.
San Francisco, California and other locations
Stereotactic Laser Ablation for Temporal Lobe Epilepsy
open to eligible people ages 18-70
The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).
San Francisco, California and other locations
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
Sorry, in progress, not accepting new patients
This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and PK of ZX008 when used as adjunctive therapy for uncontrolled seizures in pediatric and young adult subjects with Dravet syndrome. After an initial Screening and Baseline charting of seizure frequency, subjects who qualify for the study will be randomized (1:1:1) to receive either ZX008 (0.2 mg/kg/day, 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization will be stratified by age group (< 6 years, ≥6 to 18 years). All subjects will be titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects will continue treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study will undergo a 2-week taper, unless they enroll in a follow-on study. Subjects will be followed for post-study safety monitoring. Parents/caregivers will use a diary daily to record the number/type of seizures, dosing, and use of rescue medication.
San Francisco, California and other locations
Human Epilepsy Project 2: Resistant Focal Seizures Study
Sorry, not currently recruiting here
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
San Francisco, California and other locations
RNS® System Epilepsy PAS
Sorry, accepting new patients by invitation only
The purpose of the study is to follow patients with partial onset seizures prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified CECs by qualified neurologists, epileptologists, and neurosurgeons trained on the RNS System.
San Francisco, California and other locations
The Human Epilepsy Project
Sorry, in progress, not accepting new patients
HEP is a five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy.
San Francisco, California and other locations
Last updated: